Preclinical formulation in early drug research

Solubility, Delivery and ADME Problems of Drugs and Drug-Candidates

Volumn , Issue , 2011, Pages 68-85

  Balázs, Ottilia ^a  

^a GEDEON RICHTER LTD   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882728179     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.2174/978160805120511101010068     Document Type: Chapter

References (86)

1. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004; 3: 711-715.
2. Venkatesh S, Lipper RA. Role of the development scientist in compound lead selection and optimization. J Pharm Sci 2000, 89: 145-154.
3. DiMasi JA et al. The price of innovation: new estimates of drug development costs. J Health Econ 2003, 22: 151-185.
4. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Del Rev 2001, 46: 3-26.
5. Bittner B, Mountfield RJ. Formulations and Related Activities for the Oral Administration of Poorly Water-soluble Compounds in Early Discovery Animal Studies. Pharm Ind 2002, 64(9): 985-991.
6. Gardner CR, Walsh CT, Almarsson O. Drugs as materials: valuing physical form in drug discovery. Nat Rev Drug Discov 2004, 3(11): 926-934.
7. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Del Rev 1997; 23(1-3): 3-25.
8. Maas J, Kamm W, Hauck G. An integrated early formulation strategy from hit evaluation to preclinical candidate profiling. Eur J Pharm Biopharm 2007, 66: 1-10.
9. Pouton CW. Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and 'selfmicroemulsifying' drug delivery systems. Eur J Pharm Sci 2000; 11: S93-S98.
10. Strickley RG. Solubilizing excipients in oral and injectable formulations. Pharm Res 2004, 21(2): 201-230.
11. Rowe RC, Sheskey PJ, Quinn ME, editors. Handbook of Pharmaceutical Excipients. 6th ed. London, England: Pharmaceutical Press; 2009.
12. Li P, Zhao L. Developing early formulations: Practice and perspective. Int J Pharm 2007, 341: 1-19.
13. Bittner B, Mountfield RJ. Intravenous administration of poorly soluble new drug entities in early drug discovery: The potential impact of formulation on pharmacokinetic parameters. Curr Opin Drug Discov Dev 2002, 5(1): 59-71.
14. Alvarez-Nunez FA, Yalkowsky SH. Buffer capacity and precipitation control of pH solubilized phenytoin formulations. Int J Pharm 1999, 185: 45-49.
15. Gupta SL, Patel JP, Jones DL, Partipilo RW. Parenteral formulation development of rennin inhibitor Abbott-72517. J Parent Sci Technol 1994, 48: 86-91.
16. Yalkowsky SH, Roseman TJ. Solubilization of drugs by cosolvents. In: Yalkowsky SH, editor. Techniques of Solubilization of Drugs. New York, NY: Marcel Dekker Inc; 1981. pp. 91-134.
17. Kettanoh-World N. Use of experimental design in the pharmaceutical industry. J Pharm Biomed Anal 1991, 9: 605-610.
18. Millard JW, Alvarez-Nunez FA, Yalkowsky, SH. Solubilization by cosolvents establishing useful constants for the loglinear model. Int J Pharm 2002, 245: 153-166.
19. Reed KW, Yalkowsky SH. Lysis of human red blood cells in the presence of various cosolvents III. The relationship between haemolytic potential and structure. J Parent Sci Technol 1987, 41: 37-39.
20. Reed KW, Yalkowsky SH. Lysis of human red blood cells in the presence of various cosolvents II. The effect of differing NaCl concentrations. J Parent Sci Technol 1986, 40: 88-95.
21. Fu RC-C, Lindgate DM, Whatler JL, McCullough T. The biocompatibility of parenteral vehicles-in vitro/in vivo screening comparison and the effect of excipients on haemolysis. J Parent Sci Technol 1987, 41: 164-168.
22. Walters KM, Mason WD, Badr MZ. Effect of propylene glycol on the disposition of Dramamine in the rabbit. Drug Metab Dispos 1993, 21: 305-308.
23. Hugger ED, Novak BL, Burton PS, Audus KL, Borchardt RT. A comparison of commonly used polyethoxylated pharmaceutical excipients on their ability to inhibit P-glycoprotein activity in vitro. J Pharm Sci 2002, 91: 1991-2002.
24. Bassit AW, Podczeck F, et al. Influence of polyethylene glycol 400 on the gastrointestinal absorption of ranitidine. Pharm Res 2002, 19: 1368-1374.
25. Lawrence MJ. Surfactant systems: their use in drug delivery. Chem Soc Rev 1994; 417-424.
26. Torchilin VP. Micellar nanocarriers: pharmaceutical perspectives. Pharm Res 2007, 24: 1-16.
27. Rege BD, Kao JPY, Polli JE. Effects of non-ionic surfactants on membrane transporters in Caco-2 cell monolayers. Eur J Pharm Sci 2002, 16: 237-246.
28. Yu L, Bridgers A, Polli J, Vickers A, Long S, Roy A, Winnike R, Coffin M. Vitamin-E-TPGS increases absorption flux of an HIV protease inhibitor by enhancing its solubility and permeability. Pharm Res 1999, 16: 1812-1817.
29. Tayrouz Y, Ding R, Burhenne J, et al. Pharmacokinetic and pharmaceutic interaction between digoxin and Chremophor RH40. Clin Pharmacol Therap 2003, 73: 397-405.
30. Hu Z, Tawa R, Konishi T, Shibata N, Takada K. A novel emulsifier, labrasol, enhances gastrointestinal absorption of gentamicin by inhibiting transporter. Life Sci 2001, 69: 2899-2910.
31. Nerurkar MM, Ho NF, Burton PS, Vidmar TJ, Borchart RT. Mechanistic roles of neutral surfactants on concurrent polarized and passive membrane transport of a model peptide in Caco-2 cells. J Pharm Sci 1997, 86: 813-821.
32. Sha X, Yan G, WU Y, Li J, Fang X. Effect of self-microemulsifying drug delivery systems containing Labrasol on tight junctions in Caco-2 cells. Eur J Pharm Sci 2005, 24: 477-486.
33. Malingre MM, Schellens JH, Van Tellingen O, et al. The co-solvent Chremophor EL limits absorption of orally administered paclitaxel in cancer patients. Br J Cancer 2001, 85: 1472-1477.
34. Jonkman de Vries JD, Flora KP, Bult A, Beijnen JH. Pharmaceutical development of (investigational) anticancer agents for parenteral use-a review. Drug Dev Ind Pharm 1996, 22: 475-494.
35. Ten Tije AJ, Verweij J, Loos WJ, Sparreboom A. Pharmacological effects of formulation vehicles-implications for cancer chemotherapy. Clin Pharmacokinet 2003, 42: 665-685.
36. Ten Tije AJ, Loos WJ, Verweij J, Baker SD, Dinh K, Figg WD, Sparreboom A. Disposition of polyoxyethylated excipients in humans: Implications for drug safety and formulation approaches. Clin Pharmacol Ther 2003, 74(5): 509-10.
37. Van Zuylen L, Karlsson MO, Verwej J, Sparreboom A. Role of formulation vehicles in taxane pharmacology. Invest New Drugs 2001, 19: 125-141.
38. Loftsson T, Brewster ME. Pharmaceutical Applications of Cyclodextrins. 1. Drug Solubilization and Stabilization. J Pharm Sci 1996, 85(10): 1017-1025.
39. Loftsson T, Brewster ME, Máson M. Role of Cyclodextrins in improving oral drug delivery. Am J Drug Deliv 2004, 2(4): 261-275.
40. Shimpi S, Chauhan B, Shimpi P. Cyclodextrins: Application in different routes of drug administration. Acta Pharm 2005, 55: 139-156.
41. Rao VM and Stella VJ. When can cyclodextrins be considered for solubilization purposes? J Pharm Sci 2003; 92: 927-932.
42. Gould S, Scott RC. 2-Hydroxypropyl-β-cyclodextrin (HPβCD): A toxicology review. Food Chem Toxicol 2005, 43(10): 1451-9.
43. Gerloczy A, Antal S, Szatmari I, Müller-Horvath R, Szejtli J. Absorption, distribution end excretion of 14-C labelled HPβCD in rats following oral administration. In: Duchene D, editor. Minutes of the 5th International Symposium on Cyclodextrins. Paris: Editions de Sante; 1990; pp. 507-513.
44. Irie T, Uekama K. Pharmaceutical applications of cyclodextrins. III. Toxicological issues and Safety Evaluation. J Pharm Sci 1997, 86(2): 147-162.
45. Brewster ME, Anderson WR, Meinsma D, Moreno D, Webb AI, Pablo L, Estes KS, Derendorf H, Bodor N, Sawchuk R, Cheung B, Pop E. Intravenous and Oral Pharmacokinetic Evaluation of a 2-Hydroxypropyl-β-cyclodextrin-Based Formulation of Carbamazepine in the Dog: Comparison with commercially Available Tablets and Suspensions. J Pharm Sci 1997, 86(3): 335-339.
46. Müller RH, Peters K, Becker R, Kruss B. Nanosuspensions-a novel formulation for the i.v. administration of poorly soluble drugs. In: 1st World Meeting APGI/APV: 1995; Budapest. pp. 491-492.
47. Kipp JE et al. Microprecipitation method for preparing submicron suspensions. US Patent 6607784. 2003
48. Chen X, Young TJ, Sarkari M, Williams RO, Johnston KP. Preparation of cyclosporine a nanoparticles by evaporative precipitation into aqueous solution. Int J Pharm 2002; 242 (1-2): 3-14.
49. Kesisoglou F, Panmai S, Wu YH. Nanosizing-Oral formulation development and biopharmaceutical evaluation. Adv Drug Del Rev 2007, 59: 631-644.
50. Keck CM, Müller RH. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. Eur J Pharm Biopharm 2006, 62: 3-16.
51. Müller RH, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy: rationale for development and what we can expect for the future. Adv Drug Del Rev 2001, 47(1): 3-19.
52. Wong J, Brugger A, Khare A, Chaubal M, et all. Suspensions for intravenous (IV) injection: A review of development, preclinical and clinical aspects. Adv Drug Del Rev 2008, 60: 939-954.
53. Charman WN. Lipids, lipophilic drugs, and oral drug delivery-some emerging concepts. J Pharm Sci 2000, 89(8): 967-978.
54. Pinnamaneni S, Das NG, Das SK. Formulation approaches for orally administered poorly soluble drugs. Pharmazie 2002; 57 (5): 291-300.
55. Gursoy RN, Benita S. Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. Biomed Pharmacother 2004, 58(3): 173-182.
56. The HLB system: A Time-Saving Guide to Emulsifier Selection. Wilmington, Delaware: ICI Surfactants.1992; 1-21.
57. Grove M, Pedersen GP, Nielsen JL, Mullertz A. Bioavailability of seocalcitol I: relating solubility in biorelevant media with oral bioavailability in rats-effect of medium and long chain triglycerides. J Pharm Sci 2005, 94(8): 1830-1838.
58. Georgakopoulos E, Farah N, Vergnault G. Oral anhydrous non-ionic microemulsions administrated in softgel capsules. BT Gattefose. 1992, 85: 11-20.
59. Florence AT. The oral absorption of micro-and nano-particulates: neither exceptional nor unusual. Pharm Res 1997, 14: 259-266.
60. Kurihara A, Shibayama Y, Mizota A, Yasuno A, Ikeda M, Hisaoka M. Pharmacokinetics of highly lipophilic antitumor agent palmitoyl rhizoxin incorporated in lipid emulsions in rats. Biol Pharm Bull 1996, 19: 252-258.
61. Takino T, Konishi K, Takakura Y, Hashida M. Long circulating emulsion carrier systems for highly lipophilic drugs. Biol Pharm Bull 1994, 17: 121-125.
62. Vasconcelos T, Sarmento B, Costa P. Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. Drug Discov Today 2007; 12(23-24): 1068-75.
63. Leuner C, Dressman J. Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm 2000, 50: 47-60.
64. Majerik V et al. Bioavailability enhancement of an active substance by supercritical antisolvent precipitation. J Supercrit Fluids. 2007, 40: 101-110.
65. Dannenfelser RM et al. Development of clinical dosage forms for a poorly water soluble drug I: Application of polyethylene glycol-polysorbate 80 solid dispersion carrier system. J Pharm Sci 2004, 93: 1165-1175.
66. Van Drooge DJ et al. Characterization of the molecular distribution of drugs in glassy solid dispersions at the nano-meter scale, using differential scanning calorimetry and gravimetric water vapour sorption techniques. Int J Pharm 2006, 310: 220-229.
67. Van den Mooter G et al. Evaluation of Inutec SP1 as a new carrier in the formulation of solid dispersions for poorly soluble drugs. Int J Pharm 2006, 316: 1-6.
68. Yuksel N, Karatas A, Ozkan Y, Savaser A, Ozkan SA, Baykara T. Enhanced bioavailability of piroxicam using Gelucire 44/14 and Labrasol: in vitro and in vivo evaluation. Eur J Pharm Biopharm 2003, 56: 453-459.
69. Pouton CW. Formulation of poorly water-soluble drugs for oral administration: physicochemical issues and the lipid formulation classification system. Eur J Pharm Sci 2006, 29: 278-289.
70. Joshi HN, Tejwani RW, Davidovich M, et al. Bioavailability enhancement of a poorly water-soluble drug by solid dispersion in polyethylene glycol-polysorbate 80 mixture. Int J Pharm 2004, 269(1): 251-258.
71. Serrajudin ATM. Solid dispersion of poorly water-soluble drugs: Early promises, subsequent problems, and recent breakthroughs. J Pharm Sci 1999, 88(10): 1058-1066.
72. Vippagunta SR et al. Factors affecting the formation of eutectic solid dispersions and their dissolution behaviour. J Pharm Sci 2006, 96: 294-304.
73. Konno H, Taylor LS. Influence of different polymers on the crystallization tendency of molecularly dispersed amorphous felodipine. J Pharm Sci 2006, 95(12): 2692-2705.
74. Huang J et al. Nifedipine solid dispersion in microparticles of ammonio methacrylate copolymer and ethylcellulose binary blend for controlled drug delivery: Effect of drug loading on release kinetics. Int J Pharm 2006, 319: 44-54.
75. Kawakami K, Miyoshi K, Ida Y. Solubilization behaviour of poorly soluble drugs with combined use of Gelucire 44/14 and cosolvent. J Pharm Sci 2004, 93: 1471-1479.
76. Li P, Tabibi SE, Yalkowsky SH. Solubilization of ionized and un-ionized flavopiridol by ethanol and polysorbate 20. J Pharm Sci 1999, 88: 507-509.
77. He Y, Li P, Yalkowsky SH. Solubilization of fluasterone in cosolvent/ cyclodextrin combinations. Int J Pharm 2002, 264: 25-34.
78. Li P, Zhao L, Yalkowsky SH. Combined effect of cosolvent and cyclodextrin on solubilization of nonpolar drugs. J Pharm Sci 1999, 88: 1107-1111.
79. Fauci MT, Mura P. Effect of water soluble polymers on naproxen complexation with natural and chemical modified cyclodextrins. Drug Dev Ind Pharm 2001, 27: 909-917.
80. Raghavan SL, Trividic A, Davis AF, Hadgraft J. Crystallization of hydrocortisone acetate: influence of polymers. Int J Pharm 2001, 212: 213-221.
81. Usui F, Maeda K, Kusai A, et al. Inhibitory effects of water soluble polymers on precipitation of RS-8395. Int J Pharm 1997, 154: 59-66.
82. Gao P, Rush BD, Pfund WP, et al. Development of a supersaturatable SEDDS (S-SEDDS) formulation of paclitaxel with improved oral bioavailability. J Pharm Sci 2003; 92 (12): 2395-2407.
83. Gao P, Guyton ME, Huang T, et al. Enhanced oral bioavailability of a poorly water soluble drug PNU-92325 by supersaturatable formulations. Drug Dev Ind Pharm 2004, 30(2): 221-229.
84. Yalkowsky SH, Krzyzaniak JF, Ward GH. Formulation-related problems associated with intravenous drug delivery. J Pharm Sci 1998, 87: 787-796.
85. Surakitbanharn Y, Simamora P, Ward GH, Yalkowsky SH. Precipitation of pH solubilized phenytoin. Int J Pharm 1994, 109: 27-33.
86. Portmann GA, Simons DM. Microscopic determination of drug solubility in plasma and calculation of injection rates with a plasma circulatory model to prevent precipitation on intravenous injection. J Pharm Biomed Anal 1995, 13: 1189-1193.